Euticals and Intraco Chemicals sign an agreement for Euticals to acquire 40% of Pharmintraco

Euticals SpA, one of the world’s leading companies in the development and manufacture of active ingredients for the pharmaceutical industry, has signed an agreement with Intraco Chemicals Ltd for Euticals to acquire from Intraco Chemicals a 40% share of Pharmintraco GmbH, a Swiss pharmaceutical company specialised in the development and manufacture of injectable drugs by isolator technology.

The molecules developed by Euticals will substantially strengthen Pharmintraco’s existing product portfolio and will also enable Euticals to enter the market of finished products with proprietary formulations. Pharmintraco, a quality and innovation-oriented company, is focused on the aseptic processing of anti-cancer drugs by isolator technology and can therefore benefit from a wide range of active ingredients, destined to the generic oncological drug market, contained in Euticals’ development pipeline, also taking advantage of the advantageous situation deriving from the expiry of several drugs’ patent protection over the next five years.

“This is a strategic alliance that will enable both companies to reinforce and combine their individual efforts made up until now in developing molecules and finished products which target anti-cancer therapy, whilst benefiting from the competitive advantage of an integrated supply chain” said the Managing Director of Pharmintraco, Maurizio Battistini.

Maurizio Silvestri, President and Managing Director of Euticals and Andreas Tschirschnitz, the newly-appointed President of Pharmintraco, are of the same opinion and are confident that this cooperation will increase the growth potential of both companies. Thanks to this partnership, Pharmintraco will widen its product range and commercial reach, and will be able to count on Euticals’ expertise for broadening its market coverage. Thanks to this new project, Euticals intends to offer a comprehensive service to its clients, from the identification of a new product to its entire development and registration, being able to rely on a partner dedicated to the achievement of excellence.